APA (7th ed.) Citation

C, C., C, A., S, L., G, A., F, B., G, M., . . . A, F. (2018). Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. JAMA oncology, 4(4), 529. https://doi.org/10.1001/jamaoncol.2017.5314

Chicago Style (17th ed.) Citation

C, Cremolini, et al. "Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial." JAMA Oncology 4, no. 4 (2018): 529. https://doi.org/10.1001/jamaoncol.2017.5314.

MLA (9th ed.) Citation

C, Cremolini, et al. "Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial." JAMA Oncology, vol. 4, no. 4, 2018, p. 529, https://doi.org/10.1001/jamaoncol.2017.5314.